Intangible Assets

3 Months Ended

Mar. 31, 2020

Intangible Assets, Net (Excluding Goodwill) [Abstract]

INTANGIBLE ASSETS

The following table summarizes our intangible assets, net (in millions):



	March 31, 2020										December 31, 2019
	Gross Carrying Amount		Accumulated Amortization			Foreign Currency Translation Adjustment			Net Carrying Amount		Gross Carrying Amount		Accumulated Amortization			Foreign Currency Translation Adjustment			Net Carrying Amount
Finite-lived assets:
Intangible asset - sofosbuvir	$	10,720	$	(4,428	)	$	—		$	6,292	$	10,720	$	(4,253	)	$	—		$	6,467
Intangible asset - axicabtagene ciloleucel	6,200		(847		)	—			5,353		6,200		(761		)	—			5,439
Intangible asset - Ranexa	688		(688		)	—			—		688		(688		)	—			—
Other	1,098		(474		)	(7		)	617		1,098		(454		)	(6		)	638
Total finite-lived assets	18,706		(6,437		)	(7		)	12,262		18,706		(6,156		)	(6		)	12,544
Indefinite-lived assets - IPR&D	1,247		—			(7		)	1,240		1,247		—			(5		)	1,242
Total intangible assets	$	19,953	$	(6,437	)	$	(14	)	$	13,502	$	19,953	$	(6,156	)	$	(11	)	$	13,786

Aggregate amortization expense related to finite-lived intangible assets was $281 million and $299 million for the three months ended March 31, 2020 and 2019, respectively, and was primarily included in Cost of goods sold on our Condensed Consolidated Statements of Income.

The following table summarizes the estimated future amortization expense associated with our finite-lived intangible assets as of March 31, 2020 (in millions):



Fiscal Year	Amount
2020 (remaining nine months)	$	844
2021	1,124
2022	1,124
2023	1,124
2024	1,124
Thereafter	6,922
Total	$	12,262